11-Ethyl-6,8-dimethyloxazolo[5,4,3-ij]pyrido[3,2-g]quinoline-4,10(2H,11H)-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 11-Ethyl-6,8-dimethyloxazolo[5,4,3-ij]pyrido[3,2-g]quinoline-4,10(2H,11H)-dione
• 英文别名: 3-ethyl-6,10-dimethyl-15-oxa-3,13-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-1(16),2(7),5,8,10-pentaene-4,12-dione
• 化学式: C₁₇H₁₆N₂O₃
• 分子量: 296.32
• InChiKey: CLFGYIMAZCFMED-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  22
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  49.8
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• COMPOUNDS FOR TREATMENT OF FLUOROQUINOLONE-RESISTANT BACTERIA
  申请人：The Board of Trustees of the University of IIIinois

  公开号：US20170096436A1

  公开（公告）日：2017-04-06

  Compounds that specifically kill fluoroquinolone (FQ) resistant bacteria have been developed and are described herein. The FQs are the most commonly prescribed antibiotics to adults in the U.S. and thus are extremely important drugs. However, bacterial resistant to these drugs is now ubiquitous in some of the most common and deadly Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Indeed, FQs are no longer indicated for treatment of MRSA and VRE infections because of such resistance. The compounds have specific and potent activity versus MRSA and VRE.
• US9920069B2
  申请人：——

  公开号：US9920069B2

  公开（公告）日：2018-03-20
• [EN] COMPOUNDS FOR TREATMENT OF FLUORQUINOLONE-RESISTANT BACTERIA<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE BACTÉRIES RÉSISTANTES À LA FLUORQUINOLONE
  申请人：UNIV ILLINOIS

  公开号：WO2015142952A1

  公开（公告）日：2015-09-24

  Compounds that specifically kill fluoroquinolone (FQ) resistant bacteria have been developed and are described herein. The FQs are the most commonly prescribed antibiotics to adults in the U.S. and thus are extremely important drugs. However, bacterial resistant to these drugs is now ubiquitous in some of the most common and deadly Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Indeed, FQs are no longer indicated for treatment of MRSA and VRE infections because of such resistance. The compounds have specific and potent activity versus MRSA and VRE.